Sanofi shares plunged after its experimental drug for the skin condition atopic dermatitis disappointed investors with a less ...

Sanofi stock plummeted Thursday after the company's experimental eczema drug proved meaningfully inferior to Dupixent.

Shares in French drugmaker Sanofi fell more than 10% on Thursday, wiping nearly $13 billion off its market value, after ...

A trial of Sanofi’s new eczema drug has disappointed investors hoping for a replacement for its blockbuster Dupixent, sending the French pharma group’s shares down more than 9 per cent on Thursday.

Data from the late-stage trial of amlitelimab weren’t as strong as the results seen in Phase 2, adding to doubts about a drug ...

Amlitelimab has been billed by Sanofi as a successor to its Regeneron-partnered, $14.5 billion blockbuster Dupixent ...

Amlitelimab showed efficacy in skin clearance compared to a placebo, but the results underwhelmed investors.

Amgen (AMGN) stock in focus as the company and Kyowa Kirin (KYKOF) report Phase 3 data showing their atopic dermatitis drug, ...

Sanofi stated that these positive results strengthen amlitelimab's potential as a treatment for atopic dermatitis. The company is currently conducting additional late-stage trials of the drug, which ...

Sanofi (SNY) stock drops after Phase 3 trial results for amlitelimab, its experimental therapy for eczema, disappointed ...

New York City-based Pfizer earned approval from the Food and Drug Administration for its topical drug Eucrisa, reports Reuters. Eucrisa, known under the generic name crisaborole, is intended to treat ...